Acute Rhinosinusitis
Conditions
Keywords
rhinosinusitis, nasal irrigation, nasal douche, Ectoin
Brief summary
The goal of this non interventional study is to investigate the efficacy, tolerability and safety of the newly developed Ectoin Nasal Douche END01. Within the study, END01 will be used as concomitant therapy in addition to the use of a Xylometazoline-containing decongestant nasal spray. It will be investigated if the dosis of the used decongestant nasal spray might be reduced, the development of the disease might be positively influenced and/or the potentially occuring side effects (e.g. dryness of the nasal mucosa, sneezing) might be alleviated by using the Ectoin Nasal Douche as concomitant therapy.
Detailed description
The current non-interventional study aims to investigate the efficacy, tolerability and safety of a decongestant Xylometazoline-containing nasal spray in comparison to use of a decongestant Xylometazoline-containing nasal spray together with an Ectoin-containing nasal douche in patients with acute viral rhinosinusitis. Efficacy will be studied by documentation of the following symptoms: * oedema, redness (assessed by rhinoscopy) * nasal obstruction, nasal secretion, headache/face pain, loss of sense of smell/taste * sore throat, cough In parallel, participating patients will document their symptoms and the their quality of life over the entire study duration in patient diaries. Patients of both genders aged 6 years and above can take part in the study if diagnosed with acute viral rhinosinusitis. The assignment of a patient to a particular treatment is not decided in advance but falls within current practice, and is clearly separated from the decision to include the patient into the study. Study therapy will be applied in accordance with the respective instructions for use. Study duration is 7-14 days, depending on the improvement of symptoms. At the end of the study, both the investigators and the patients are asked to judge the efficacy and tolerability of the treatments.
Interventions
Application of Xylometazoline Nasal Spray in accordance with the instructions for use
DEVICEEctoin Nasal Douche
Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
Sponsors
Bitop AG
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Inclusion criteria
* patients with acute viral rhinosinusitis * presence of common cold symptoms
Exclusion criteria
* contraindications in accordance with instructions for use * acute bacterial rhinosinusitis * chronic rhinosinusitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Physicians' assessment of change of intensity of rhinosinusitis symptoms | day 0 and day 7 and (if necessary, depending on study duration) and on day 14 | Both on day 0 and on day 7 (and, if necessary, depending on study duration, on day 14), the physicians will assess rhinosinusitis symptoms oedema, redness of the nose, nasal obstruction, nasal secretion, facial pain/headache, smell/taste dysfunction and the concomitant symptoms dryness of the nasal mucosa and sore throat. Assessment will be carried out based on a 5-point scale (0=none to 4=very strong). Change of symptoms will be assessed comparing symptom scores on day 7 (or day 14, if applicable) to day 0. The investigators will use rhinoscopy, physical examination and interview of the patients for the assessments. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physicians' assessment of general well-being of patients | day 0 and day 7 and day 14 (if necessary, depending on study duration) | The investigators will assess the well-being of patients using a 4-point scale (good condition to strong illness). |
| Patients' assessment of intensity of symptoms and their influence on quality of life | 7 to 14 days (depending on study duration) | Patients will document their rhinosinusitis symptoms and their influence on quality of life (22 parameters in accordance with the sino-nasal outcome test-22 questionnaire) and the additional symptom dry nose. They will document their judgement daily in a patient diary using a 6-point scale (0=no problem to 5=as bad as possible). |
| Assessment of the efficacy of treatments | day 7 or day 14 (depending on study duration) | At the end of the study, both investigators and patients will judge the overall efficacy of the treatment based on a 6-point scale (1=very good to 6=unsatisfactory). |
| Assessment of the tolerability of treatments | day 7 or day 14 (depending on study duration) | Both investigators and patients will judge the tolerability of the treatments at the end of the study. Both investigators and patients will judge the tolerability based on a 6 point scale (1=very good to 6 = unsatisfactory). |
| Incidence of adverse events/serious adverse events | 7 to 14 days (depending on study duration) | All occurring adverse events/serious adverse events will be documented during the entire study period. |
Countries
Germany
Outcome results
None listed